AU2015312252B2 - Tasimelteon for treating Smith-Magenis Syndrome - Google Patents

Tasimelteon for treating Smith-Magenis Syndrome Download PDF

Info

Publication number
AU2015312252B2
AU2015312252B2 AU2015312252A AU2015312252A AU2015312252B2 AU 2015312252 B2 AU2015312252 B2 AU 2015312252B2 AU 2015312252 A AU2015312252 A AU 2015312252A AU 2015312252 A AU2015312252 A AU 2015312252A AU 2015312252 B2 AU2015312252 B2 AU 2015312252B2
Authority
AU
Australia
Prior art keywords
tasimelteon
sleep
melatonin
improvement
sms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015312252A
Other languages
English (en)
Other versions
AU2015312252A1 (en
Inventor
Christian Lavedan
Mihael H. Polymeropoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015312252(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of AU2015312252A1 publication Critical patent/AU2015312252A1/en
Application granted granted Critical
Publication of AU2015312252B2 publication Critical patent/AU2015312252B2/en
Priority to AU2020239640A priority Critical patent/AU2020239640B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Processing Of Solid Wastes (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Led Device Packages (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coils Or Transformers For Communication (AREA)
AU2015312252A 2014-09-02 2015-08-29 Tasimelteon for treating Smith-Magenis Syndrome Active AU2015312252B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020239640A AU2020239640B2 (en) 2014-09-02 2020-09-22 Tasimelteon for treating smith-magenis syndrome

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020239640A Division AU2020239640B2 (en) 2014-09-02 2020-09-22 Tasimelteon for treating smith-magenis syndrome

Publications (2)

Publication Number Publication Date
AU2015312252A1 AU2015312252A1 (en) 2017-03-30
AU2015312252B2 true AU2015312252B2 (en) 2020-07-02

Family

ID=54147267

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015312252A Active AU2015312252B2 (en) 2014-09-02 2015-08-29 Tasimelteon for treating Smith-Magenis Syndrome
AU2020239640A Active AU2020239640B2 (en) 2014-09-02 2020-09-22 Tasimelteon for treating smith-magenis syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020239640A Active AU2020239640B2 (en) 2014-09-02 2020-09-22 Tasimelteon for treating smith-magenis syndrome

Country Status (17)

Country Link
US (5) US10179119B2 (OSRAM)
EP (2) EP3188727B1 (OSRAM)
JP (3) JP6903571B2 (OSRAM)
KR (2) KR20170048541A (OSRAM)
CN (2) CN116098887A (OSRAM)
AU (2) AU2015312252B2 (OSRAM)
BR (1) BR112017003644A2 (OSRAM)
CA (2) CA2957588C (OSRAM)
DK (1) DK3188727T3 (OSRAM)
ES (1) ES2936833T3 (OSRAM)
FI (1) FI3188727T3 (OSRAM)
HR (1) HRP20230070T1 (OSRAM)
HU (1) HUE061051T2 (OSRAM)
MX (1) MX386150B (OSRAM)
PT (1) PT3188727T (OSRAM)
SI (1) SI3188727T1 (OSRAM)
WO (1) WO2016036619A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014841A (es) * 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de agonista de melatonina.
HRP20230070T1 (hr) * 2014-09-02 2023-03-17 Vanda Pharmaceuticals Inc. Tasimelteon za liječenje smith-magenis sindroma
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
CN113365618A (zh) * 2018-09-12 2021-09-07 万带兰制药公司 改善睡眠或睡醒后表现
MX2022006577A (es) * 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.
TWI891877B (zh) 2020-08-27 2025-08-01 日商友華股份有限公司 檢查裝置
CA3229930A1 (en) * 2021-09-14 2023-03-23 Mihael Polymeropoulos Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025606A1 (en) 1996-12-10 1998-06-18 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
MX2008014841A (es) 2006-05-22 2008-12-05 Vanda Pharmaceuticals Inc Tratamiento de agonista de melatonina.
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP4502609A3 (en) * 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
HRP20230070T1 (hr) * 2014-09-02 2023-03-17 Vanda Pharmaceuticals Inc. Tasimelteon za liječenje smith-magenis sindroma
MX2022006577A (es) * 2019-12-13 2022-07-04 Vanda Pharmaceuticals Inc Formulaciones liquidas de tasimelteon y metodos para su uso.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rudiger Hardeland, "New approches in the management of insomnia: weighing the advantage of prolonged-release melatonin and synthetic melatoninergic agnists", neuropsychiatric disease and treatment *
van thillo a et al, "sleep disturbance in smith-magenis syndrome: treatment with melatonin and beta-adrenergic antagonists", tijdschrift voor psychiatrie *

Also Published As

Publication number Publication date
EP3188727A1 (en) 2017-07-12
AU2020239640A1 (en) 2020-10-15
AU2015312252A1 (en) 2017-03-30
CA2957588C (en) 2021-08-31
MX386150B (es) 2025-03-18
NZ765911A (en) 2023-08-25
PT3188727T (pt) 2023-01-30
NZ729901A (en) 2020-09-25
FI3188727T3 (fi) 2023-02-20
KR20240015729A (ko) 2024-02-05
CA2957588A1 (en) 2016-03-10
KR20170048541A (ko) 2017-05-08
EP3188727B1 (en) 2022-11-09
AU2020239640B2 (en) 2020-11-05
JP2020143159A (ja) 2020-09-10
CN116098887A (zh) 2023-05-12
HUE061051T2 (hu) 2023-05-28
JP7132277B2 (ja) 2022-09-06
EP4137129A1 (en) 2023-02-22
JP2022078291A (ja) 2022-05-24
DK3188727T3 (da) 2023-02-06
US20240293355A1 (en) 2024-09-05
SI3188727T1 (sl) 2023-03-31
US20190105297A1 (en) 2019-04-11
CA3124872A1 (en) 2016-03-10
US10653665B2 (en) 2020-05-19
US10179119B2 (en) 2019-01-15
HRP20230070T1 (hr) 2023-03-17
MX2017002796A (es) 2017-06-09
BR112017003644A2 (pt) 2017-11-28
US11266622B2 (en) 2022-03-08
JP7252390B2 (ja) 2023-04-04
WO2016036619A1 (en) 2016-03-10
US20170239210A1 (en) 2017-08-24
CN106604726A (zh) 2017-04-26
US20200237712A1 (en) 2020-07-30
JP2017526693A (ja) 2017-09-14
ES2936833T3 (es) 2023-03-22
US20220133681A1 (en) 2022-05-05
JP6903571B2 (ja) 2021-07-14

Similar Documents

Publication Publication Date Title
AU2020239640B2 (en) Tasimelteon for treating smith-magenis syndrome
Yukuhiro et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
EA015256B1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
Ray et al. Effects of the second-generation" bath salt" cathinone alpha-pyrrolidinopropiophenone (α-PPP) on behavior and monoamine neurochemistry in male mice
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
CA3067929C (en) New uses of a pure 5-ht6 receptor antagonist
CN112367998B (zh) 用组胺-3受体反向激动剂进行治疗的方法
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
JP2019516696A (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
EP3607948A1 (en) Tissue transglutaminase modulators for medicinal use
TW202515540A (zh) 使用三重再攝取抑制劑治療睡眠障礙之方法
EA042685B1 (ru) Новые применения чистого антагониста 5-ht6 рецептора

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)